Try our beta test site
283 studies found for:    expanded access studies cancer
Show Display Options
Rank Status Study
1 No longer available Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
Condition: Advanced Breast Cancer (Female)
Interventions: Drug: Palbociclib;   Drug: Letrozole
2 Terminated Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)
Condition: Prostate Cancer
Intervention: Drug: Oral Satraplatin
3 Approved for marketing Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic
Intervention: Drug: TAS-102
4 Approved for marketing Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study
Condition: Cancer of the Prostate
Intervention: Drug: C-11 Choline PET Imaging
5 No longer available Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Alectinib
6 Active, not recruiting Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
Condition: Metastatic Prostate Cancer
Intervention: Drug: 11C-choline Injection
7 No longer available Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy
Condition: Metastatic Renal Cell Cancer
Intervention: Drug: Everolimus
8 Available Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion
Conditions: Cancer;   Neurotrophic Tyrosine Kinase, Receptor-related Proteins
Intervention: Drug: larotrectinib
9 Approved for marketing EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
10 Approved for marketing Expanded Access of Cabozantinib in Medullary Thyroid Cancer
Condition: Medullary Thyroid Cancer
Intervention: Drug: cabozantinib
11 Approved for marketing An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Condition: Metastatic Breast Cancer
Intervention: Drug: Eribulin Mesylate
12 Completed An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001
Condition: Prostate Neoplasms
Interventions: Drug: Abiraterone acetate;   Drug: Glucocorticoid
13 Available Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation;   Triple-Negative Breast Cancer
Interventions: Drug: Veliparib;   Drug: Cisplatin;   Drug: Vinorelbine
14 Available Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Condition: Ovarian Cancer
Intervention: Drug: Olaparib tablets
15 Completed Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: RAD001
16 Approved for marketing Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Condition: Metastatic Castration-Resistant Prostate Cancer
Intervention: Drug: MDV3100
17 Active, not recruiting An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
Conditions: Non Small Cell Lung Cancer (NSCLC);   Cancer of the Head and Neck (H&N)
Intervention: Drug: ZD1839
18 Available An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC
Conditions: Malignant Neoplasms of Digestive Organs;   Neuroendocrine Tumor;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System
Interventions: Drug: 68Ga-DOTATOC;   Procedure: PET/CT
19 Available Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
Condition: Cancers With NTRK, ROS1, or ALK Gene Fusions
Intervention: Drug: Entrectinib
20 Terminated
Has Results
Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers
Condition: Cancer
Intervention: Drug: Mifepristone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.